LUCIRA HEALTH INC (LHDX) Stock Price, Forecast & Analysis
NASDAQ:LHDX • US54948U1051
LHDX Key Statistics, Chart & Performance
The current stock price of LHDX is 0.4523 USD. In the past month the price increased by 17.18%. In the past year, price decreased by -89.13%.
LHDX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to LHDX. When comparing the yearly performance of all stocks, LHDX is a bad performer in the overall market: 87.4% of all stocks are doing better.
LHDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LHDX. Both the profitability and financial health of LHDX have multiple concerns.
LHDX Financial Highlights
Over the last trailing twelve months LHDX reported a non-GAAP Earnings per Share(EPS) of -3.19. The EPS decreased by -84.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.48 |
LHDX Forecast & Estimates
6 analysts have analysed LHDX and the average price target is 0.77 USD. This implies a price increase of 69.14% is expected in the next year compared to the current price of 0.4523.
For the next year, analysts expect an EPS growth of 83% and a revenue growth 201.55% for LHDX
LHDX Ownership
LHDX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.98 | 199.24B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.52 | 175.441B | ||
| SYK | STRYKER CORP | 25.4 | 145.828B | ||
| BSX | BOSTON SCIENTIFIC CORP | 20.98 | 111.449B | ||
| BDX | BECTON DICKINSON AND CO | 11.48 | 51.993B | ||
| IDXX | IDEXX LABORATORIES INC | 44.37 | 51.841B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.05 | 47.817B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.73 | 38.306B | ||
| RMD | RESMED INC | 20.56 | 36.658B | ||
| DXCM | DEXCOM INC | 28.98 | 28.507B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LHDX
Company Profile
Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 221 full-time employees. The company went IPO on 2021-02-05. The firm is focused on providing disposable, single use test kit platform to replace central lab testing for diagnosing infectious diseases which leads to treatment and disease control outcomes. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. The company is also engaged in the commercialization of commercializing its PCR-quality COVID-19 test kits. Through its polymerase chain reaction (PCR)-quality technology, the Company offers single-use testing for infectious diseases. Its test kits are coupled with its digital platform, LUCI PASS, which is designed to securely deliver a clinically relevant test result to users at home, healthcare providers, and to required public health authorities. The firm has its operations in United States and Canada, among others.
Company Info
LUCIRA HEALTH INC
1315 63Rd Street
Emeryville CALIFORNIA 94608 US
CEO: Erik T. Engelson
Employees: 221
Phone: 18145741546.0
LUCIRA HEALTH INC / LHDX FAQ
Can you describe the business of LUCIRA HEALTH INC?
Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 221 full-time employees. The company went IPO on 2021-02-05. The firm is focused on providing disposable, single use test kit platform to replace central lab testing for diagnosing infectious diseases which leads to treatment and disease control outcomes. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. The company is also engaged in the commercialization of commercializing its PCR-quality COVID-19 test kits. Through its polymerase chain reaction (PCR)-quality technology, the Company offers single-use testing for infectious diseases. Its test kits are coupled with its digital platform, LUCI PASS, which is designed to securely deliver a clinically relevant test result to users at home, healthcare providers, and to required public health authorities. The firm has its operations in United States and Canada, among others.
What is the current price of LHDX stock?
The current stock price of LHDX is 0.4523 USD. The price decreased by -19.23% in the last trading session.
Does LUCIRA HEALTH INC pay dividends?
LHDX does not pay a dividend.
How is the ChartMill rating for LUCIRA HEALTH INC?
LHDX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is LUCIRA HEALTH INC (LHDX) stock traded?
LHDX stock is listed on the Nasdaq exchange.
What is LUCIRA HEALTH INC worth?
LUCIRA HEALTH INC (LHDX) has a market capitalization of 18.36M USD. This makes LHDX a Nano Cap stock.
What is the next earnings date for LHDX stock?
LUCIRA HEALTH INC (LHDX) will report earnings on 2023-05-10.